Literature DB >> 15259375

Presence of secretory group IIa and V phospholipase A2 and cytosolic group IValpha phospholipase A2 in chondrocytes from patients with rheumatoid arthritis.

Lilian Leistad1, Astrid J Feuerherm, Monika Ostensen, Arild Faxvaag, Berit Johansen.   

Abstract

Both secretory and cytosolic phospholipase A2 enzymes have been implicated in the pathogenesis of arthritis in animal models, but the exact expression patterns of the enzymes in diseased human joint tissue are uncertain. We investigated the messenger RNA expression of group IIa, IValpha and V phospholipase A2 and localized the presence of group IIa and IValpha phospholipase A2 at protein levels in articular cartilage from patients with rheumatoid arthritis, osteoarthritis and patients with non-arthritic joints. Both group IIa phospholipase A2 messenger RNA and protein were detected in all samples independent of diagnosis, but were far more prominent in cartilage from rheumatoid arthritis samples. In cartilage with rheumatoid arthritis, the enzyme was detected both within the chondrocytes and in the extracellular matrix, whereas only few osteoarthritic cartilage samples showed positive staining in the matrix. In the cartilage matrix of non-arthritic controls, group IIa phospholipase A2 was totally absent. Messenger RNA for the group IValpha and V phospholipase A2 was, except for one osteoarthritic cartilage sample, exclusively detected in rheumatoid arthritic cartilage. For group IValpha phospholipase A2 this was also confirmed at the protein level. These results suggest that each phospholipase A2 enzyme has distinct roles in both healthy and diseased joint tissue, and that the diversity and amount of enzyme correlate with the grade of inflammation and disease severity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15259375     DOI: 10.1515/CCLM.2004.104

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  10 in total

1.  Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A2 responsive liposome in prostate cancer.

Authors:  J N Mock; L J Costyn; S L Wilding; R D Arnold; B S Cummings
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

Review 2.  Enzyme-Responsive Liposomes for the Delivery of Anticancer Drugs.

Authors:  Farnaz Fouladi; Kristine J Steffen; Sanku Mallik
Journal:  Bioconjug Chem       Date:  2017-03-08       Impact factor: 4.774

3.  Molecular basis of phospholipase A2 activity toward phospholipids with sn-1 substitutions.

Authors:  Lars Linderoth; Thomas L Andresen; Kent Jørgensen; Robert Madsen; Günther H Peters
Journal:  Biophys J       Date:  2007-09-07       Impact factor: 4.033

4.  Cytosolic phospholipase A2 alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model.

Authors:  Nobuyuki Tai; K Kuwabara; M Kobayashi; K Yamada; T Ono; K Seno; Y Gahara; J Ishizaki; Y Hori
Journal:  Inflamm Res       Date:  2009-08-05       Impact factor: 4.575

Review 5.  Persisting eicosanoid pathways in rheumatic diseases.

Authors:  Marina Korotkova; Per-Johan Jakobsson
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

6.  Articular inflammation induced by an enzymatically-inactive Lys49 phospholipase A2: activation of endogenous phospholipases contributes to the pronociceptive effect.

Authors:  Renata Gonçalves Dias; Sandra Coccuzzo Sampaio; Morena Brazil Sant'Anna; Fernando Queiroz Cunha; José María Gutiérrez; Bruno Lomonte; Yara Cury; Gisele Picolo
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2017-03-23

Review 7.  Stimulus-Responsive Nanomedicines for Disease Diagnosis and Treatment.

Authors:  Gengqi Liu; Jonathan F Lovell; Lei Zhang; Yumiao Zhang
Journal:  Int J Mol Sci       Date:  2020-09-02       Impact factor: 5.923

8.  Antibody-induced pain-like behavior and bone erosion: links to subclinical inflammation, osteoclast activity, and acid-sensing ion channel 3-dependent sensitization.

Authors:  Alexandra Jurczak; Lauriane Delay; Julie Barbier; Nils Simon; Emerson Krock; Katalin Sandor; Nilesh M Agalave; Resti Rudjito; Gustaf Wigerblad; Katarzyna Rogóż; Arnaud Briat; Elisabeth Miot-Noirault; Arisai Martinez-Martinez; Dieter Brömme; Caroline Grönwall; Vivianne Malmström; Lars Klareskog; Spiro Khoury; Thierry Ferreira; Bonnie Labrum; Emmanuel Deval; Juan Miguel Jiménez-Andrade; Fabien Marchand; Camilla I Svensson
Journal:  Pain       Date:  2021-11-19       Impact factor: 7.926

9.  Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.

Authors:  Maung-Maung Thwin; Eleni Douni; Pachiappan Arjunan; George Kollias; Prem V Kumar; Ponnampalam Gopalakrishnakone
Journal:  Arthritis Res Ther       Date:  2009-09-18       Impact factor: 5.156

10.  Endothelial protein C receptor-associated invasiveness of rheumatoid synovial fibroblasts is likely driven by group V secretory phospholipase A2.

Authors:  Meilang Xue; Kaitlin Shen; Kelly McKelvey; Juan Li; Yee-Ka Agnes Chan; Vicky Hatzis; Lyn March; Christopher B Little; Michael Tonkin; Christopher J Jackson
Journal:  Arthritis Res Ther       Date:  2014-02-05       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.